Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 158

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 158
---
 condensed consolidated financial statements. We have determined that our most critical accounting estimates are those relating to revenue recognition, accrued research and development expenses and stock-based compensation. As of September 30, 2025, there have been no material changes to our existing critical accounting estimates discussed in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2024.

25

Results of Operations

Comparison of the three and nine months ended September 30, 2025 and 2024

Revenues

Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Revenues:Product revenue, net$12,880 $8,964 $34,061 $25,768 Total revenue$12,880 $8,964 $34,061 $25,768 

Total Revenue - Three Months Ended September 30, 2025 vs. Three Months Ended September 30, 2024 – The increase in total revenue of $3.9 million for the three months ended September 30, 2025 compared to the three months ended September 30, 2024 was due to increased volume associated with PYRUKYND®.

Total Revenue - Nine Months Ended September 30, 2025 vs. Nine Months Ended September 30, 2024 – The increase in total revenue of $8.3 million for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 was due to increased volume associated with PYRUKYND®.

Total Operating ExpensesThree Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Operating expenses:Cost of sales$1,679 $783 $4,466 $2,905 Research and development86,796 72,455 251,479 218,476 Selling, general and administrative41,274 38,537 128,670 105,087 Total operating expenses$129,749 $111,775 $384,615 $326,468 

Total Operating Expenses -  Three Months Ended September 30, 2025 vs. Three Months Ended September 30, 2024 – The increase in total operating expenses of $18.0 million for the three months ended September 30, 2025 compared to the three months ended September